NEWS

19-03-18
Vitafoods Europe 2018

 

15-17 May 2018

Geneva

 

Meet us at stand K72

Rifencin, natural remedy for gastrointestinal disorders

A highly bioavailable anti-inflammatory and gastro-intestinal protector

Rifencin® is an innovative formulation combining two drug substances: curcumin from a turmeric dry extract in a highly soluble form and sweet fennel essential oil.

 

With no side effects, Rifencin® can be used for long periods without digestive complications.

 

Rifencin® improves all the aspects of the quality of life of the patients with functional gastrointestinal disorders.

 

 

Rifencin Formulation

Rifencin® is a gelatin soft capsule of 920 mg containing turmeric rhizome dry extract (Curcuma longa L.) and sweet fennel essential oil (Foeniculum vulgare Mill. subsp. vulgare var. dulce (Mill.) Batt. & Trab.) in the form of oily gel formulation.

 

Each soft capsule contains a quantity of turmeric extract corresponding to 42.0 mg of curcumin and 25 mg of sweet fennel essential oil.

 

Rifencin® recommended dosage is 2 capsules twice a day before a meal for one month, then 2 capsules once a day.

 

Rifencin and GI Disease

Rifencin® is a natural remedy whose active principals act on the symptoms of gastro-intestinal disorders like :

 

  • Irritable Bowel Disease (IBD),
  • Irritable Bowel Syndrome (IBS).

 

The combination of curcumin and fennel offers a combination of complementary active principals.

 

Curcumin is known in traditional medicine for its capacity to increase bile production, to help relieve the symptoms of indigestion :

 

  • feeling of "full stomach"
  • flatulence
  • slow digestion

 

Fennel is also traditionally known for the symptomatic treatment of :

 

  • mild gastrointestinal spastic disorders
  • flatulence
  • bloating

Rifencin Clinical Data

 

 Rifencin® is delivered with a complete package of information, including bioXtract proprietary:

 

 

  •  Pre-clinical acute oral toxicity trial in rats showing no particular effect and classifying the product in the danger 5 category DL50 superior 5,000 mg/kg.
  • Phase I clinical trial demonstrating bioavailability of Rifencin®'s active principals. (Complete report available on request)


  • Phase II randomised, double-blind, multicentre, placebo controlled clinical trial evaluating the efficacy of Rifencin® in 120 patients suffering from functional gastrointestinal symptoms on a period of 30 days
    • Rifencin® was significantly superior to placebo in reducing functional gastrointestinal symptoms

    • A significantly higher number of patients in the Rifencin® group had symptom remission, compared to the placebo group

    • Symptoms improvement in significantly higher in Rifencin® group at each assesement Day (day 10, 20, 30)

    •  Rifencin® improves all aspects of Quality of Life in patients with functional gastrointestinal disorders

    •  Rifencin® has an excellent safety profile

 

 

  • Observational clinical study, prospective, not-randomized, real-life of Rifencin ® on 253 patients suffering from Intestinal Bowel Syndrome (IBS)